The Newly Diagnosed Myeloma Patient – Therapeutic Approaches

European Oncology, 2010;6(1):81-4 DOI:


The outcome for myeloma patients has significantly improved over the last decade, mainly due to the introduction of new drugs with a singular mechanism of action such as thalidomide and lenalidomide (revlimid), both immunomodulatory drugs (IMIDs), and the proteasome inhibitor bortezomib (velcade). In newly diagnosed young patients, induction regimens such as bortezomib–thalidomide or lenalidomide plus dexamethasone will replace vincristine, doxorubicin and dexamethasone (VAD), followed by high-dose melphalan. Maintenance with IMIDs may represent the new standard of care for young multiple myeloma (MM) patients. This approach is being challenged by continuous treatment with novel agents and the postponement of a transplant until relapse. Allogeneic transplant should be conducted within the context of clinical trials. In elderly patients or non-transplant candidates, new regimens based on melphalan–prednisone plus thalidomide, velcade or lenalidomide have become new standards. The reduction of side effects while maintaining efficacy of treatment is most important in the elderly population.
Keywords: Thalidomide, lenalidomide, bortezomib, autologous transplant, allogeneic transplant, side effects, thrombosis, peripheral neuropathy, complete response
Disclosure: Jesús San-Miguel has participated in advisory boards for Millennium, Celgene and Janssen-Cilag.
Received: September 28, 2009 Accepted March 16, 2010
Correspondence: Jesús San-Miguel, Servicio de Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, 37007 Salamanca, Spain. E:

The outcome for myeloma patients has significantly improved over the last decade, mainly due to the introduction of new drugs with a singular mechanism of action, such as thalidomide and lenalidomide (revlimid), both immunomodulatory drugs (IMIDs), and the proteasome inhibitor bortezomib (velcade).1 In this article, we will briefly review the treatment of newly diagnosed patients stratified according to age (above or below 65–70 years of age) and transplant or non-transplant candidate status.
Treatment of Newly Diagnosed Transplant Candidate Patients
The combination of vincristine, doxorubicin and dexamethasone (VAD) has long been the gold standard as a preparatory regimen for young newly diagnosed multiple myeloma (MM) patients who are candidates for autologous stem cell transplant (ASCT), with partial response (PR) rates ranging between 52 and 63% and complete response (CR) rates of 3–13%. However, novel drug combinations appear to be superior to VAD, such as regimens to decrease tumour burden pre-transplant (Trx). Three randomised trials have compared thalidomide (T)-based regimens (T + Dex or TAD or T + VAD) versus either high-dose DEX or VAD as an initial therapy in transplant-eligible patients.2–4 In all studies, thalidomide combinations were superior to conventional induction treatment, although the response rate (>PR) obtained with T + Dex (63%) was lower than that achieved with TAD or T + VAD (80%, but CR rates are usually <10%). The MRC group has compared cyclosphophamide + TD versus cyclophosphamide + VAD (CVAD) as an induction regimen before transplant; the thalidomide arm was significantly superior, with a response rate (RR) of 87 versus 75% including 20 versus 12% CRs, respectively. In studies evaluating bortezomib (Bz) combination therapy, data from both a French randomised trial comparing Bz + Dex versus VAD and an Italian trial comparing Bz-TD versus TD show superiority of Bz regimens both before and after transplant, with 80 versus 94% >PR including 15 versus 32% CR, respectively. These results are consistent with several previous pilot studies. In terms of lenalidomide (Len), two large randomised studies have shown that the majority of patients (>85%) respond to Len + Dex induction, but probably a minimum of six cycles would be required to achieve a substantial number of CRs.5 Novel agents did not affect stem cell collection, although for lenalidomide it is recommended to collect the cells after no more than four to six cycles using cyclophosphamide with G-CSF. In summary, current results indicate that novel induction regimens are superior to VAD.
Autologous Stem Cell Transplant
High-dose therapy (HDT) (usually based on melphalan 200mg/m2) followed by ASCT prolonged overall survival (OS) compared with standard-dose therapy (SDT) in prospective randomised trials conducted by French (Francophone Myeloma Intergroup [IFM]) and English (Medica Research Council [MRC]) groups and has provided evidence for a more than 10-year survival rate in at least a subset of patients.6,7 Nevertheless, the US study (Southwest Oncology Group [SWOG] 9321), the French MAG91 study and the Spanish PETHEMA-94 trial, although confirmed the benefit of ASCT in terms of response rate and event-free survival (EFS), did not find superiority in terms of survival compared with SDT.8,9 These discrepancies can be, at least in part, explained by: differences in study design (the Spanish study randomised patients responding to initial therapy while, in the others, randomisation was performed up-front); differences in the conditioning regimens; and, particularly, differences in the intensity and duration of the chemotherapy arm (the dose of alkylating agents and steroids were higher in the SWOG and Spanish trials, which may explain why OS for conventionally treated patients was longer in these two studies compared with the IFM and MRC trials. Despite these discrepancies, HDT is currently considered the standard of care for younger patients with MM, mainly based on the benefit on response rate and EFS.
  1. San-Miguel J, Harousseau JL, Joshua D, Anderson KC, Individualizing treatment of patients with myeloma in the era of novel agents, J Clin Oncol, 2008;26:2761-2766.
  2. Rajkumar SV, Rosiñol L, Hussein M, et al., Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma, J Clin Oncol, 2008;26:2171-2177.
  3. Cavo M, Zamagni E, Tosi P, et al., Superiority of thalidomide and dexamethasone over vincristinedoxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma, Blood, 2005;106:35-39.
  4. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al., Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma, Haematologica, 2008;93:124-127.
  5. Niesvizky R, Jayabalan DS, Christos PJ, et al., BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma, Blood, 2008;111:1101-1109.
  6. Attal M, Harousseau JL, Stoppa AM, et al., A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome, N Engl J Med, 1996;335:91-97.
  7. Child JA, Morgan GJ, Davies FE, et al., High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N Engl J Med, 2003;348:1875-1883.
  8. Barlogie B, Kyle RA, Anderson KC, et al., Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321, J Clin Oncol, 2006;24:929-936.
  9. Blade J, Rosinol L, Sureda A, et al., High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA, Blood, 2005;106:3755-3759.
  10. Attal M, Harousseau JL, Facon T, et al., Single versus double autologous stem-cell transplantation for multiple myeloma, N Engl J Med, 2003;349:2495-2502.
  11. Cavo M, Tosi P, Zamagni E, et al., Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study, J Clin Oncol, 2007;25:2434-2441.
  12. Attal M, Harousseau JL, Leyvraz S, et al., Maintenance therapy with thalidomide improves survival in patients with multiple myeloma, Blood, 2006;108:3289-3294.
  13. Spencer A, Prince HM, Roberts AW, et al., Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure, J Clin Oncol, 2009;27:1788-1793.
  14. Barlogie B, Tricot G, Anaissie E, et al., Thalidomide and hematopoietic-cell transplantation for multiple myeloma, N Engl J Med, 2006;354:1021-1030.
  15. Barlogie B, Pineda-Roman M, Van RF, et al., Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities, Blood, 2008;112:3115-3121.
  16. Garban F, Attal M, Michallet M, et al., Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma, Blood, 2006;107:3474-3480.
  17. Bruno B, Rotta M, Patriarca F, et al., A comparison of allografting with autografting for newly diagnosed myeloma, N Engl J Med, 2007;356:1110-1120.
  18. Rosinol L, Perez-Simon JA, Sureda A, et al., A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma, Blood, 2008;112:3591-3593.
  19. Facon T, Mary JY, Hulin C, et al., Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial, Lancet, 2007;370:1209-1218.
  20. Palumbo A, Bringen S, Caravita T, et al., Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial, Lancet, 2006;367:825–31
  21. San Miguel J, Schlag R, Khuageva N, et al., A Phase 3 Study Comparing Bortezomib+Melphalan+Prednisone (VMP) with Melphalan+Prednisone (MP) in Newly Diagnosed Multiple Myeloma, N Engl J Med, (2008)359(9):906-17.
Keywords: Thalidomide, lenalidomide, bortezomib, autologous transplant, allogeneic transplant, side effects, thrombosis, peripheral neuropathy, complete response